(19)
(11)EP 3 885 344 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
08.12.2021 Bulletin 2021/49

(43)Date of publication A2:
29.09.2021 Bulletin 2021/39

(21)Application number: 21166266.3

(22)Date of filing:  05.11.2015
(51)International Patent Classification (IPC): 
C07D 403/04(2006.01)
A61P 35/02(2006.01)
A61K 31/437(2006.01)
C07D 401/04(2006.01)
C07D 405/14(2006.01)
A61P 35/00(2006.01)
A61K 31/506(2006.01)
C07D 401/02(2006.01)
C07D 403/14(2006.01)
C07D 471/04(2006.01)
(52)Cooperative Patent Classification (CPC):
C07D 403/14; C07D 471/04; C07D 417/04; A61K 31/437; A61P 35/02; C07D 401/04; C07D 401/14; A61P 43/00; C07D 403/04; C07D 413/04; A61K 31/506; A61P 35/00; C07D 405/14
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 05.11.2014 CN 201410619334
01.04.2015 CN 201510152615

(62)Application number of the earlier application in accordance with Art. 76 EPC:
15857419.4 / 3216786

(71)Applicant: InventisBio Co., Ltd.
Building 63, Pudong Shanghai 201203 (CN)

(72)Inventor:
  • JIANG, Yueheng
    Pudong, Shanghai 201203 (CN)

(74)Representative: Hansen, Norbert 
Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3
80335 München
80335 München (DE)


(56)References cited: : 
  
      


    (54)PYRIMIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USES THEREOF


    (57) The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).





    Search report





















    Search report